Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aria: PRAX-114 in Major Depressive Disorder
NCT04832425Phase 3Completed
- Sponsor
- Praxis Precision Medicines
- Start
- Mar 2021
- Primary completion
- May 2022
- Modality
- Allosteric Modulators
- Countries
- 2
01
Overview
A Phase 3 trial of PRAX-114 in major depressive disorder (MDD), sponsored by Praxis Precision Medicines. Started Mar 2021; status: completed.
02
Drugs
PRAX-114
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04832425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04832425.